GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (NAS:IPHA) » Definitions » Net Margin %

Innate Pharma (Innate Pharma) Net Margin % : -56.10% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Innate Pharma Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Innate Pharma's Net Income for the six months ended in Dec. 2023 was $-10.13 Mil. Innate Pharma's Revenue for the six months ended in Dec. 2023 was $18.06 Mil. Therefore, Innate Pharma's net margin for the quarter that ended in Dec. 2023 was -56.10%.

The historical rank and industry rank for Innate Pharma's Net Margin % or its related term are showing as below:

IPHA' s Net Margin % Range Over the Past 10 Years
Min: -2166.15   Med: -75.7   Max: 22.51
Current: -14.59


IPHA's Net Margin % is ranked better than
69.72% of 1027 companies
in the Biotechnology industry
Industry Median: -162.84 vs IPHA: -14.59

Innate Pharma Net Margin % Historical Data

The historical data trend for Innate Pharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Net Margin % Chart

Innate Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -30.26 -113.94 -436.06 -117.19 -14.59

Innate Pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -764.24 15.27 -775.13 4.86 -56.10

Competitive Comparison of Innate Pharma's Net Margin %

For the Biotechnology subindustry, Innate Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innate Pharma's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where Innate Pharma's Net Margin % falls into.



Innate Pharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Innate Pharma's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-8.255/56.599
=-14.59 %

Innate Pharma's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-10.129/18.056
=-56.10 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innate Pharma  (NAS:IPHA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Innate Pharma Net Margin % Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Innate Pharma (Innate Pharma) Business Description

Traded in Other Exchanges
Address
117, Avenue de Luminy, Marseille, FRA, 13009
Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.